Kutatási jelek – Signal Engine

• PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti‑PD‑1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial — Ovarian cancer
• 148 Using real‑world data from GlioCova to assess the feasibility and revise the design of the ARISTOCRAT trial in recurrent glioblastoma — Glioblastoma
• Novel Studies Seek to Optimize HER2+ Breast Cancer Management — Breast cancer
• Dr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations — NSCLC
• FDA Grants Fast Track Designation to ZL-1310 in Extensive Stage SCLC — SCLC
• The Good Cancer? — Thyroid cancer
• Reaching Consensus on Defining, Treating High‑Risk Myeloma — Multiple myeloma
• Neoadjuvant Pembrolizumab Produces High pCR Rate With No Relapses at 3 Years in High‑Risk dMMR/MSIHigh CRC — Colorectal cancer
• Imfinzi Shows Significant Survival Benefits in Limited-Stage Small-Cell Lung Cancer in Phase III ADRIATIC Trial — NSCLC
• Standard of Care and Treatment Challenges in Gastric Cancer — Gastric cancer
• Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point — Follicular lymphoma
• Evidence Suggests Bidirectional Risk Between Ovarian, Colorectal Cancers — Ovarian cancer
• B7‑H3‑Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer — SCLC
• Next Steps for KRAS Inhibitors Focus on Tackling Resistance — NSCLC
• Treatment Selection and Sequencing Strategies for Advanced EGFR-mutated NSCLC in the Second-Line Setting — NSCLC
• New Drugs Being Explored in Kidney Cancer — Renal cell carcinoma
• CTIM-76 Receives FDA Fast Track Designation for Platinum‑Resistant Ovarian Cancer — Ovarian cancer
• EGFR Mutations in NSCLC — NSCLC
• EGFR-Targeted Therapy for Squamous NCSLC — Lung cancer
• Drs Lee and Saxena on Future Directions for PD-L1 Evaluation in EGFR-Mutated NSCLC — NSCLC